Pancreatic Cancer Research

ResearcherColumbia UniversityNo recent work listed

Charles S. Fuchs

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1582-9842; OpenAlex author ID A5049314303; NIH RePORTER profile ID 1901896. Sources: ClinicalTrials.gov.

Their work

Papers
66 (first author 0, last author 8)
Trials
2 (principal investigator on 2)
Grants
2
Labs led
2
Collaborators
150
Papers, trials and grants by year

1998: 1 trial · 1999: none · 2000: none · 2001: none · 2002: none · 2003: none · 2004: none · 2005: none · 2006: none · 2007: 1 trial · 2008: none · 2009: none · 2010: none · 2011: 4 papers · 2012: 5 papers, 1 grant · 2013: 10 papers · 2014: 5 papers · 2015: 4 papers · 2016: 4 papers · 2017: 4 papers · 2018: 8 papers · 2019: 6 papers · 2020: 8 papers · 2021: 5 papers · 2022: none · 2023: 3 papers, 1 grant

Papers 50 of 66

  1. Genetic Susceptibility to Nonalcoholic Fatty Liver Disease and Risk for Pancreatic Cancer: Mendelian Randomization. Co-author DOI 10.1158/1055-9965.epi-23-0453↗
  2. Sex-Specific Associations between Adiponectin and Leptin Signaling and Pancreatic Cancer Survival. Co-author DOI 10.1158/1055-9965.epi-23-0505↗
  3. Helicobacter pylori Seropositivity, ABO Blood Type, and Pancreatic Cancer Risk From 5 Prospective Cohorts. Co-author DOI 10.14309/ctg.0000000000000573↗
  4. Impact of Diabetes and Insulin Use on Prognosis in Patients With Resected Pancreatic Cancer: An Ancillary Analysis of NRG Oncology RTOG 9704. Co-author DOI 10.1016/j.ijrobp.2020.08.042↗
  5. Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies. Co-author DOI 10.1093/ajcn/nqab217↗
  6. Prediagnostic Inflammation and Pancreatic Cancer Survival. Co-author DOI 10.1093/jnci/djab040↗
  7. Smoking Modifies Pancreatic Cancer Risk Loci on 2q21.3. Co-author DOI 10.1158/0008-5472.can-20-3267↗
  8. Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3141↗
  9. Diabetes, Weight Change, and Pancreatic Cancer Risk. Co-author DOI 10.1001/jamaoncol.2020.2948↗
  10. Endocrine-Exocrine Signaling Drives Obesity-Associated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.cell.2020.03.062↗
  11. A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djz246↗
  12. Genome-Wide Association Study Data Reveal Genetic Susceptibility to Chronic Inflammatory Intestinal Diseases and Pancreatic Ductal Adenocarcinoma Risk. Co-author DOI 10.1158/0008-5472.can-20-0447↗
  13. Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-19-1315↗
  14. Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population. Co-author DOI 10.1158/1055-9965.epi-19-1389↗
  15. Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Co-author DOI 10.1158/1055-9965.epi-20-0275↗
  16. Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-20-0651↗
  17. Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated … Last author DOI 10.1007/s10637-018-0650-5↗
  18. Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk. Co-author DOI 10.1038/s41416-019-0426-5↗
  19. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Co-author DOI 10.1038/s41436-018-0009-5↗
  20. Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djy155↗
  21. Endocrine-exocrine signaling drives obesity-associated pancreatic ductal adenocarcinoma Co-author DOI 10.1101/663583↗
  22. Prediagnostic Leukocyte Telomere Length and Pancreatic Cancer Survival. Co-author DOI 10.1158/1055-9965.epi-19-0577↗
  23. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamaoncol.2017.3420↗
  24. Statin use and pancreatic cancer risk in two prospective cohort studies. Co-author DOI 10.1007/s00535-018-1430-x↗
  25. Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2018.02.022↗
  26. Plasma inflammatory cytokines and survival of pancreatic cancer patients. Co-author DOI 10.1038/s41424-018-0008-5↗
  27. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/s41467-018-02942-5↗
  28. Regular Use of Aspirin or Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs Is Not Associated With Risk of Incident Pancreatic Cancer in Two Large Cohort Studie… Co-author DOI 10.1053/j.gastro.2017.12.001↗
  29. iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-17-1090↗
  30. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Co-author DOI 10.1158/2159-8290.cd-18-0275↗
  31. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. Co-author DOI 10.1038/bjc.2017.349↗
  32. Leucocyte telomere length, genetic variants at the TERT gene region and risk of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2016-312510↗
  33. Cigarette Smoking and Pancreatic Cancer Survival. Co-author DOI 10.1200/jco.2016.71.2026↗
  34. Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer. Last author DOI 10.1634/theoncologist.2016-0447↗
  35. Circulating Metabolites and Survival Among Patients With Pancreatic Cancer. Co-author DOI 10.1093/jnci/djv409↗
  36. Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms. Co-author DOI 10.1158/0008-5472.can-16-1699↗
  37. Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study. Co-author DOI 10.1158/1055-9965.epi-15-1217↗
  38. Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival. Co-author DOI 10.1200/jco.2015.66.3005↗
  39. TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.29590↗
  40. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Co-author DOI 10.1038/ng.3341↗
  41. Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studies. Co-author DOI 10.1093/annonc/mdv355↗
  42. Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus. Co-author DOI 10.1200/jco.2014.57.5688↗
  43. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Co-author DOI 10.1038/nm.3686↗
  44. Dairy products and pancreatic cancer risk: a pooled analysis of 14 cohort studies. Co-author DOI 10.1093/annonc/mdu019↗
  45. 25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance). Co-author DOI 10.1093/jnci/dju185↗
  46. Genome-wide association study of survival in patients with pancreatic adenocarcinoma. Co-author DOI 10.1136/gutjnl-2012-303477↗
  47. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Co-author DOI 10.1634/theoncologist.2014-0086↗
  48. Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Co-author DOI 10.1007/s10552-012-0078-8↗
  49. Polymorphisms in genes related to one-carbon metabolism are not related to pancreatic cancer in PanScan and PanC4. Co-author DOI 10.1007/s10552-012-0138-0↗
  50. Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastat… Co-author DOI 10.1007/s11136-012-0217-4↗

Trials 2

  1. RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer Principal investigator NCT00409292↗
  2. Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer Principal investigator NCT00251355↗

Grants 2

  1. Project 3 - Improving Therapy for DNA-Damage Deficient Pancreatic Adenocarcinoma P50CA127003↗
  2. Prospective Cohort Collaborative in Pancreatic Cancer Epidemiology & Pathogenesis R01CA124908↗

Closest collaborators

The 25 strongest of 150 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Brian Matthew Wolpin · 38 shared papers, 1 shared grant, 2011–2023 · strength 2.85
  2. Chen Yuan · 23 shared papers, 2014–2023 · strength 1.60
  3. Kimmie Ng · 23 shared papers, 2012–2023 · strength 1.58
  4. Ana Babić · 20 shared papers, 2016–2023 · strength 1.48
  5. Edward L. Giovannucci · 27 shared papers, 2011–2023 · strength 1.46
  6. Peter Kraft · 22 shared papers, 2012–2023 · strength 1.34
  7. Vicente Morales‐Oyarvide · 16 shared papers, 2016–2021 · strength 1.04
  8. Jonathan Andrew Nowak · 13 shared papers, 2017–2023 · strength 0.98
  9. JoAnn E. Manson · 16 shared papers, 2012–2023 · strength 0.97
  10. Douglas Adam Rubinson · 16 shared papers, 2014–2021 · strength 0.94
  11. Natalia I. Khalaf · 10 shared papers, 2017–2021 · strength 0.70
  12. Zhi Rong Qian · 14 shared papers, 2013–2019 · strength 0.65
  13. Ralph Weissleder · 1 shared grant, 2023 · strength 0.61
  14. Albert C. Koong · 7 shared papers, 2017–2021 · strength 0.47
  15. Richard Francis Dunne · 7 shared papers, 2017–2021 · strength 0.47
  16. Daniel Tandel Chang · 7 shared papers, 2017–2021 · strength 0.47
  17. Aram F. Hezel · 7 shared papers, 2017–2021 · strength 0.47
  18. Kimberly J. Perez · 5 shared papers, 2019–2023 · strength 0.46
  19. Andrew J. Aguirre · 6 shared papers, 2018–2021 · strength 0.44
  20. Tsuyoshi Hamada · 6 shared papers, 2018–2020 · strength 0.43
  21. Ying Bao · 11 shared papers, 2011–2020 · strength 0.42
  22. Laufey Thora Amundadottir · 8 shared papers, 2013–2020 · strength 0.39
  23. Thomas E. Clancy · 6 shared papers, 2015–2021 · strength 0.36
  24. Jihye Kim · 3 shared papers, 2020–2023 · strength 0.36
  25. Rachael Z. Stolzenberg‐Solomon · 11 shared papers, 2011–2020 · strength 0.36

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.